Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.385
-0.065-1.19%
Volume:5.44M
Turnover:29.21M
Market Cap:8.59B
PE:-17.11
High:5.545
Open:5.500
Low:5.250
Close:5.450
52wk High:13.150
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:0.81
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-89.13%
ROA:-18.89%
PB:11.94
PE(LYR):-17.11
PS:27.32

Loading ...

CStone Pharmaceuticals' Application for Tumor Drug Gets China Nod in 23 Days

MT Newswires Live
·
Aug 21

CSTONE PHARMA-B Gets NMPA Green Light for CS5007 Investigational New Drug Application

Stock News
·
Aug 21

CStone Says China NMPA Clears IND for Cs5007 Egfr/her3 Bispecific ADC

Reuters
·
Aug 21

CStone Pharmaceuticals - Receives Nmpa Ind Approval for Cs5007 in China

THOMSON REUTERS
·
Aug 21

CStone Pharma Cuts Outstanding Shares by 4.47 Million in July; Confirms Public-Float Compliance

Bulletin Express
·
Aug 06

CStone Pharma Sets 27 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend

Bulletin Express
·
Aug 06

Cstone Pharmaceuticals Says Directors and Senior Management Purchase 2.4 Million Shares in June 2026

Reuters
·
Jul 23

CStone directors and executives acquire 2.42 million shares; company cancels 4.60 million buy-backs as CS2009 advances toward global Phase III

Bulletin Express
·
Jul 23

Key Insider Purchases at CStone Pharma-B, Reflecting Confidence in Future Prospects

Stock News
·
Jul 23

Cstone Pharmaceuticals - Directors and Senior Management Purchase 2.4 Mln Shares in June 2026

THOMSON REUTERS
·
Jul 23

Cstone Pharmaceuticals - Company to Initiate Global Phase Iii Mrcts for Cs2009 by End of 2026

THOMSON REUTERS
·
Jul 23

CStone Highlights Promising Phase I/II Data for Trispecific Antibody CS2009 Ahead of ESMO 2026

Bulletin Express
·
Jul 20

CStone Pharma's CS2009 Tri-Specific Antibody Data Accepted for ESMO 2026 Presentation

Stock News
·
Jul 20

CStone Pharma Reports Stable Share Capital in June; 4.60 Million Shares Repurchased Pending Cancellation

Bulletin Express
·
Jul 07

CStone Pharmaceuticals (SEHK:2616) Expands Sugemalimab Reach As Valuation Questions Linger

Simply Wall St.
·
Jul 05

CStone Pharma completes HKD 21.35 million share buybacks, 0.29% of share capital awaiting cancellation

Bulletin Express
·
Jun 29

Cstone Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jun 29

CStone Pharmaceuticals-B Shares Surge Over 6% in Early Trading Following Exclusive Commercialization Deal for Sugemalimab in Australia and New Zealand

Deep News
·
Jun 29

CStone Pharmaceuticals-B Executes Share Buyback on June 25

Stock News
·
Jun 26

Cstone Pharmaceuticals Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jun 26